8-K - Pulse Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Pulse Biosciences, Inc. announced long-term follow-up data from its nPulse™ Vybrance™ Percutaneous Electrode System first-in-human feasibility study for benign thyroid nodule ablation, showing average 74% volume reduction at 15-22 months with no regrowth, no serious adverse events, and high patient satisfaction. The data were presented at the North American Society for Interventional Thyroidology 2026 meeting.

Key Takeaways

1Study monitored 21 patients at 15-22 months post-treatment

2Average 74% volume reduction of treated benign thyroid nodules

3100% patient cosmetic satisfaction at final follow-up

495% patient overall satisfaction at final follow-up

5No regrowth of nodules and no serious adverse events reported

6No intranodular fibrosis detected on ultrasounds

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 9, 2026, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing long-term follow-up data from its nPulse™ Vybrance™ Pe

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated March 9, 2026 - Pulse Bios

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 9, 2026